COMP <GO>
NVAX vs JNJ // PIOTROSKI F-SCORE QUALITY
Novavax Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NVAX 7
— JNJ 5
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $10.08 (-3.72%) • MKT CAP: $1.73B
piotroski-score
5/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVAX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVAX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.50% | 67.90% | +25.60 | NVAX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 25.50% | +59.50 | NVAX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.3x | 18.5x | -15.20 | NVAX | /valuation <GO> |
| Free Cash Flow Yield | -14.17% | 2.97% | -17.14 | JNJ | /fcf-yield <GO> |
| Operating Margin | 40.30% | 34.70% | +5.60 | NVAX | /operating-margins <GO> |
| Net Profit Margin | 39.20% | 28.50% | +10.70 | NVAX | /net-margins <GO> |
| Revenue Growth (YoY) | 64.70% | 6.00% | +58.70 | NVAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 62.1 | -13.80 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 23.0x | -19.50 | NVAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.73B | $662.49B | -$660.76B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVAX REV | JNJ REV | NVAX GROSS % | JNJ GROSS % | NVAX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.12B | $94.19B | 93.5% | 67.9% | -$244.6M | $19.70B |
| FY 2024 | $682.2M | $88.82B | 70.3% | 69.1% | -$87.3M | $19.84B |
| FY 2023 | $983.7M | $85.16B | — | — | -$714.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVAX // BETA —
JNJ // BETA 1.08